NRD
HRMY icon

Nebula Research & Development’s Harmony Biosciences HRMY Stock Holding History

Nebula Research & Development’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,403
Closed -$550K – 405
2025
Q2 		$550K Buy
17,403
+348
+2% +$11.2K 0.05% 615
2025
Q1 		$566K Sell
17,055
-1,505
-8% -$54K 0.05% 579
2024
Q4 		$639K Buy
+18,560
New +$638K 0.08% 462

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's HRMY Position: Q3 2025 in Review

Nebula Research & Development sold out of Harmony Biosciences (HRMY) in Q3 2025, closing a stake of 17,403 shares — an estimated $550K sold.

Nebula Research & Development first reported a position in HRMY in Q4 2024 and held it in 3 quarters. The position peaked at $639K in Q4 2024. 296 funds tracked by Wall St. Rank hold HRMY as of Q3 2025.

  • Nebula Research & Development reported no remaining Harmony Biosciences position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 17,403 Harmony Biosciences shares in Q3 2025, an estimated $550K.
  • Nebula Research & Development first reported a position in Harmony Biosciences in Q4 2024 and held it in 3 quarters.
  • Nebula Research & Development's Harmony Biosciences position peaked at $639K in Q4 2024.
  • 296 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.